To reduce confounding by indication, we restricted our analysis to women with T2D who had used second-line ADMs periconceptionally and compared noninsulin vs insulin treatments, much like a hypothetical clinical trial would have pregestational T2D as an inclusion criterion and use of insulin as an active comparator. The gene discussed is INS; the disease is type 2 diabetes mellitus.